Table 3 Details of the microbiological resistance pattern of the matched-cohort study population (n = 72)

Amoxicillin

13/13

(100.0%)

4/4

(100.0%)

0/3

(0.0%)

Amoxicillin + Clavulanic Acid

14/23

(60.9%)

3/12

(25.0%)

0/3

(0.0%)

Ampicillin

13/13

(100.0%)

1/1

(100.0%)

0/3

(0.0%)

Ampicillin + Sulbactam

n/a

n/a

1/1

(100.0%)

0/1

(0.0%)

Cefazolin

14/23

(60.9%)

3/12

(25.0%)

0/3

(0.0%)

Cefepim

13/22

(59.1%)

3/11

(27.3%)

n/a

n/a

Cefotaxim

22/22

(100.0%)

12/12

(100.0%)

6/6

(100.0%)

Cefoxitin

11/18

(61.1%)

3/8

(37.5%)

n/a

n/a

Cefoxitin Screen

8/10

(80.0%)

1/4

(25.0%)

n/a

n/a

Ceftriaxon

13/22

(59.1%)

3/11

(27.3%)

n/a

n/a

Cefuroxim

14/23

(60.9%)

3/12

(25.0%)

n/a

n/a

Cephalexin

n/a

n/a

1/1

(100.0%)

n/a

n/a

Chloramphenicol

1/14

(7.1%)

1/5

(20.0%)

n/a

n/a

Ciprofloxacin

8/21

(38.1%)

1/9

(11.1%)

n/a

n/a

Clarithromycin

15/23

(65.2%)

1/12

(8.3%)

1/4

(25.0%)

Clindamycin

11/23

(47.8%)

1/12

(8.3%)

0/6

(0.0%)

Cotrimoxazol

2/22

(9.1%)

0/10

(0.0%)

n/a

n/a

Daptomycin

2/22

(9.1%)

0/10

(0.0%)

n/a

n/a

Doxycyclin

9/23

(39.1%)

3/12

(25.0%)

n/a

n/a

Erythromycin

9/16

(56.3%)

1/5

(20.0%)

0/1

(0.0%)

Fosfomycin

3/23

(13.0%)

0/12

(0.0%)

n/a

n/a

Fusidic Acid

10/23

(43.5%)

0/12

(0.0%)

n/a

n/a

Gentamicin

5/22

(22.7%)

1/11

(9.1%)

n/a

n/a

Imipenem

n/a

n/a

1/1

(100.0%)

0/3

(0.0%)

Levofloxacin

8/22

(36.4%)

1/11

(9.1%)

n/a

n/a

Linezolid

1/22

(4.5%)

0/11

(0.0%)

n/a

n/a

Mecillinam

22/22

(100.0%)

12/12

(100.0%)

6/6

(100.0%)

Meropenem

n/a

n/a

1/1

(100.0%)

0/6

(0.0%)

Moxifloxacin

6/22

(27.3%)

1/12

(8.3%)

n/a

n/a

Mupirocin

1/4

(25.0%)

0/12

(0.0%)

n/a

n/a

Oxacillin

14/23

(60.9%)

3/12

(25.0%)

n/a

n/a

Penicillin

n/a

n/a

1/1

(100.0%)

0/6

(0.0%)

Penicillin V

n/a

n/a

1/1

(100.0%)

n/a

n/a

Piperacillin

22/22

(100.0%)

12/12

(100.0%)

6/6

(100.0%)

Piperacillin + Tazobactam

n/a

n/a

1/1

(100.0%)

1/3

(33.3%)

Rifampicin

1/22

(4.5%)

2/11

(18.2%)

n/a

n/a

Teicoplanin

6/19

(31.6%)

0/10

(0.0%)

n/a

n/a

Tigecyclin

0/16

(0.0%)

1/5

(20.0%)

n/a

n/a

Vancomycin

0/23

(0.0%)

0/10

(0.0%)

0/6

(0.0%)